[Gastrointestinal mucosa-associated lymphoma].

Wolfgang Fischbach, Andreas Neubauer, Gabriele Reinartz

Abstract readEnglish Abstract

In one paragraph

Article in Innere Medizin (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wolfgang FischbachMedizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg-Alzenau, Akademisches Lehrkrankenhaus der Universität Würzburg, Aschaffenburg, Deutschland. wuk.fischbach@gmail.com.

Andreas NeubauerKlinik für Innere Medizin mit Schwerpunkt Hämatologie, Onkologie und Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Carreras Leukämie Zentrum, Philipps-Universität Marburg, Baldingerstraße 1, 35043, Marburg, Deutschland.ORCID http://orcid.org/0000-0002-7606-8760

Gabriele ReinartzKlinik für Strahlentherapie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland.ORCID http://orcid.org/0000-0002-4869-5986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucosa-associated lymphomas of the gastrointestinal tract are a heterogeneous group differing in pathogenesis, localization and therapeutic options. For all of them, differentiated treatment requires an exact determination of lymphoma stage. For gastric MALT lymphoma, the pathogenetic role of Helicobacter pylori infection has become evident in the last 30 years. These insights were consequently implemented into clinical practice. Nowadays, Helicobacter pylori eradication is the treatment of choice for gastric MALT lymphoma, leading to complete remission of the lymphoma in the majority of cases. In the absence of success, radiotherapy is available in localized stages I/II E with excellent results. Immuno-chemotherapy is the domain for advanced stages III/IV E, and surgery plays no role any more. The rare intestinal and colorectal MALT lymphomas require an individualized therapeutic approach.

Indexed as

Helicobacter InfectionsLymphoma, B-Cell, Marginal ZoneCombined Modality TherapyGastrointestinal NeoplasmsHelicobacter pyloriHumansNeoplasm StagingStomach NeoplasmsHelicobacter pyloriMucosa-associated lymphoid tissueMucosa-associated lymphoma/chemotherapyMucosa-associated lymphoma/immunotherapyMucosa-associated lymphoma/radiotherapy

Identifiers

PMID38833003

DOI10.1007/s00108-024-01715-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.